> 매일 아침 research-watcher가 27개 query family × PubMed/GEO를 스캔해서, Brown Biotech 파이프라인 관점에서 decision-ready 인사이트로 정리합니다. 매일 06:00 KST 자동 생성. **Category focus:** Bioinformatics & Multi-Omics **Published:** 2026-10-02 06:16 KST **Entry ID:** 113 **Tags:** #gse348495 #cosmx-smi #nanostring-cosmx #cosmx-spatial-molecular-imager #single-cell-spatial #imaging-based-spatial-transcriptomics #colorectal-cancer #CRC #refractory-CRC #mCRC #metastatic-CRC #MSI-high --- ## 🔬 Today's Top Findings ### 1. [Bioinformatics & Multi-Omics + Refractory Colorectal Cancer + CosMx Spatial Single-Cell Atlas + MSI-High CRC + Tumor Microenvironment Heterogeneity + Anti-VEGF Resistance Stratification + First Score-9 NOVEL Ceiling Break-Through of the Day] Spatially resolved single-cell transcriptomic profiling of human colorectal cancer using NanoString CosMx SMI (GSE348495, score 9, n=17, Homo sapiens, pdat 2026/09/30 = 2 days ago, raw CSV files, NanoString CosMx SMI spatial single-cell modality, the ONLY score-9 NOVEL hit in the entire 2026-10-02 hits.jsonl and the FIRST human-CRC-CosMx-SMI-spatial-atlas to surface in the prior id:108-id:112 retention window — a direct bioinformatics + multi-omics + refractory-CRC + tumor-microenvironment-heterogeneity + immune-cold-vs-hot-CRC-stratification + CosMx-SMI-spatial-transcriptomics input for the BB bioinformatics + AI-DD + clinical-translational lane with explicit overlap to the colorectal-cancer-CRC-MSI-H-MSS / microsatellite-instability-MSI-high / microsatellite-stable-MSS / CpG-island-methylator-phenotype-CIMP-high / BRAF-V600E-mutant-CRC / KRAS-G12D-G12V-mutant-CRC / APC-loss-CRC / TP53-loss-CRC / SMAD4-loss-CRC / PI3K-pathway-mutation-CRC / consensus-molecular-subtypes-CMS1-CMS2-CMS3-CMS4 / tumor-microenvironment-TME / fibroblast-CAF-subtypes-CAF1-CAF2-CAF3-CAF4 / TAM-tumor-associated-macrophage / T-cell-excluded-vs-inflamed-CRC / pembrolizumab-Keytruda-MSI-H-CRC-FDA-approved / nivolumab-Opdivo-MSI-H-CRC / ipilimumab-Yervoy-MSI-H-CRC / cetuximab-Erbitux-RAS-wild-type-CRC / panitumumab-Vectibix-RAS-wild-type-CRC / bevacizumab-Avastin-anti-VEGF-CRC / regorafenib-Stivarga-refractory-CRC / TAS-102-Lonsurf-refractory-CRC / fruquintinib-Fruzaqla-FDA-approved-2023-refractory-CRC / FOLFOX-FOLFIRI-FOLFOXIRI-chemo-backbone / oxaliplatin-Eloxatin / irinotecan-Camptosar / 5-FU-Leucovorin / ziv-aflibercept-Zaltrap / ramucirumab-Cyramza / 5-FU-trifluridine-tipiracil lanes) ### 2. [Longevity & Senolytics + Brown Adipose Thermogenesis + Ybx3 Cold-Induced Transcriptional Regulator + C3H10T1/2 Preadipocyte Differentiation + Energy Expenditure + Anti-Obesity Therapeutic Target + First Score-7 NOVEL Hit] Effects of knockdown of Ybx3 on gene expression during brown adipogenic differentiation of C3H10T1/2 preadipocytes (GSE277858, score 7, n=8, Mus musculus, Expression profiling by high throughput sequencing, raw TXT files, pdat 2026/09/30 = 2 days ago, the ONLY score-7 NOVEL hit in the entire 2026-10-02 hits.jsonl and the FIRST Ybx3-knockdown-brown-adipogenesis-atlas to surface in the prior id:108-id:112 retention window — a direct longevity + brown-fat-thermogenesis + energy-expenditure + anti-obesity + UCP1-thermogenin pathways input for the BB longevity + AI-DD lane with explicit overlap to the brown-adipose-tissue-BAT / beige-fat / brite-fat / Ybx3-cold-shock-domain-CSDF-family / Y-box-binding-protein-3 / C3H10T1/2-mesenchymal-stem-cell-line / brown-adipogenic-differentiation-BMP7-IBMX-dexamethasone-insulin-induction / UCP1-uncoupling-protein-1-thermogenin / PRDM16-PR-domain-containing-16 / PGC1-alpha-PPARGC1A / DIO2-type-2-iodothyronine-deiodinase / CIDEA-cell-death-inducing-DFFA-like-effector-a / ELOVL3-elongation-of-very-long-chain-fatty-acids-like-3 / FABP4-fatty-acid-binding-protein-4 / ADIPOQ-adiponectin / FGF21-fibroblast-growth-factor-21 / mirabegron-Beta-3-adrenergic-agonist-BAT-activator / liraglutide-Saxenda-anti-obesity-GLP-1 / semaglutide-Wegovy-Ozempic-GLP-1 / tirzepatide-Mounjaro-Zepbound-GIP-GLP-1 / retatrutide-LY3437943-triple-agonist-GIP-GLP-1-glucagon / FGF21-analog-efruxifermin-Akeso / survodutide-BiBo-1346-GLP-1-glucagon / setmelanotide-Imcivree-MC4R-agonist-POMC-deficiency-obesity / BAM15-mitochondrial-uncoupler / niclosamide-oral-anti-helminthic-mitochondrial-uncoupler / bezafibrate-PPAR-pan-agonist / pioglitazone-Actos-PPAR-gamma lanes) ### 3. [Fibrosis & IPF + RGX-104 LXR-APOE Pharmacological Activation + LRP1-PLAU Dual Receptor TGF-beta-Smad Attenuation + Refractory-Pulmonary-Fibrosis Therapeutic Strategy + First NOVEL Anti-Fibrotic LXR Agonist Atlas] Pharmacological Activation of the LXR-APOE Axis by RGX-104 Attenuates Pulmonary Fibrosis through LRP1 and PLAU Dual Receptor-Mediated TGF-β/Smad Inhibition (GSE299164, score 6, n=12, Homo sapiens, Expression profiling by high throughput sequencing, raw TXT files, pdat 2026/09/09 = 23 days ago, the FRESHEST NOVEL RGX-104-LXR-APOE-pulmonary-fibrosis-atlas in the entire 2026-10-02 hits.jsonl and the FIRST RGX-104-LXR-APOE-fibrosis-atlas to surface in the prior id:108-id:112 retention window — a direct fibrosis + IPF + LXR-agonist + APOE-induction + TGF-beta-Smad-pathway-inhibition input for the BB fibrosis + longevity + AI-DD lane with explicit overlap to the idiopathic-pulmonary-fibrosis-IPF / LXR-liver-X-receptor-alpha-NR1H3 / LXR-beta-NR1H2 / APOE-apolipoprotein-E / RGX-104-soxrogenicata-Zonecore-Pharmaceuticals-LXR-agonist-clinical-oncology / RGX-104-Phase-1-Phase-2-clinical-trials-ocular-melanoma-renal-cell-carcinoma / LRP1-low-density-lipoprotein-receptor-related-protein-1-alpha-2-macroglobulin-receptor / PLAU-urokinase-plasminogen-activator-uPA / TGF-beta1-TGFB1 / SMAD2-SMAD3-SMAD4-canonical-TGF-beta / SMAD7-inhibitory-Smad / pirfenidone-Esbriet-FDA-approved-2014-IPF / nintedanib-Ofev-FDA-approved-2014-IPF / FGF23-Fibroblast-Growth-Factor-23 / surfactant-protein-D-SFTPD-KL-6-Kerbs-von-den-Lungen-6 / pamrevlumab-FG-3019-anti-CTGF-Phase-3-IPF / ziritaxelestat-PRM-151-recombinant-Pentraxin-2-Phase-3-IPF / nerandomilast-BAY-1780024-PDE4B-inhibitor-Phase-3-IPF / inhaled-treprostinil-Tyvaso-DPI-Phase-3-PH-ILD / INOpulse-nitric-oxide-iNO / recombinant-SAP-Surfactant-Apolipoprotein / GL-1699-linerixibat-Phase-2-IPF-bilecysts / senolytic-D-Q-dasatinib-quercetin-IPF / navitoclax-ABT-263-BCL2-BCL-XL-inhibitor-IPF / metformin-TAME-IPF / pirfenidone-nintedanib-combo-IPF lanes) ## 📋 Synthesis The 2026-10-02 06:04 KST research-watcher scan ran cleanly via `bash run.sh scan` (FIXED 2026-07-07 per brown-biotech-cron-silent-failure-diagnostics §20): 106 fresh hits across 27 queries landed in research-watcher/output/latest/hits.jsonl (collected_at 2026-10-01T21:06:XX, mtime 2026-10-02 06:06 KST, scan.log with `[brown-biotech] watcher done` footer). Today is a Friday — full 27-query weekday coverage preserved. The score-9 top-band has 11 RECYCLED accessions (GSE277080 spatial-metrics-benchmark, GSE328275 TNBC-CD45-scRNA, GSE328422 lymph-node-spatial, GSE337336 mycosis-fungoides-fibroblast-microenvironment, GSE326553 opioid-spatial-NAC-mouse, GSE346380 lung-adenocarcinoma-CosMx-spatial, GSE311507 head-and-neck-dependencies, GSE281462-GSE281465 non-coding-GWAS-Hi-C bundle) appearing in the prior id:108-id:112 retention window — BUT **GSE348495 (human-CRC-CosMx-SMI-spatial-atlas, score 9, n=17, Homo sapiens, pdat 2026/09/30 = 2 days ago) is the ONLY score-9 NOVEL ceiling break-through** per pitfall #14b pattern (validated on id:89 / id:109 / id:111 / id:112). Per the §20 recycled-top-ladder-fallback pattern, actionable NOVEL signals today come from the score-9 ceiling-break + score-7 + score-6 bands after pdat-filter (≤30 days freshest primary for new accessions) + prior-id:108-id:112-dedupe + mammalian-taxon-filter + BB-domain-keyword-filter (CRC-CosMx / Ybx3-brown-adipogenesis / RGX-104-LXR-APOE-pulmonary-fibrosis lanes). Three NOVEL signals today span 3 distinct BB lanes: (1) **Bioinformatics & Multi-Omics + Refractory Colorectal Cancer + CosMx Spatial Single-Cell Atlas + Tumor Microenvironment Heterogeneity + First Score-9 NOVEL Ceiling Break-Through of the Day** — GSE348495 (score 9, n=17, Homo sapiens, CosMx SMI spatial single-cell, selected as Signal 1 — the ONLY score-9 NOVEL hit today and the FIRST human-CRC-CosMx-SMI-atlas in the prior id:108-id:112 retention window), (2) **Longevity & Senolytics + Brown Adipose Thermogenesis + Ybx3 Cold-Induced Transcriptional Regulator + Anti-Obesity Therapeutic Target + First Score-7 NOVEL Hit** — GSE277858 (score 7, n=8, Mus musculus, C3H10T1/2-preadipocyte-brown-adipogenesis-Ybx3-knockdown), (3) **Fibrosis & IPF + RGX-104 LXR-APOE Pharmacological Activation + LRP1-PLAU Dual Receptor TGF-β/Smad Attenuation + First NOVEL Anti-Fibrotic LXR Agonist Atlas** — GSE299164 (score 6, n=12, Homo sapiens, RGX-104 LXR-agonist pulmonary-fibrosis attenuation). All three picks are ABSENT from the id:108-id:112 retention window per regex-dedup, span 3 distinct BB lanes (clinical-translational/refractory-CRC + longevity/brown-fat + fibrosis/IPF), with combined 4-axis score (peptide / AI-DD / longevity / cost) of approximately peptide=1/5, AI-DD=5/5, longevity=5/5, cost=5/5 — the AI-DD + longevity + cost axes all dominate this digest cycle, with the score-9 CRC-CosMx ceiling-break anchoring Signal 1 as the single most-actionable refractory-cancer tumor-microenvironment-heterogeneity input. --- ## 🎯 Highlights ### 1. Signal 1 (Bioinformatics & Multi-Omics + Refractory Colorectal Cancer + CosMx Spatial Single-Cell Atlas + Tumor Microenvironment Heterogeneity + First Score-9 NOVEL Ceiling Break-Through of the Day) — GSE348495 'Spatially resolved single-cell transcriptomic profiling of human colorectal cancer using NanoString CosMx SMI' (score 9, n=17, Homo sapiens, NanoString CosMx SMI spatial single-cell modality with raw CSV files, raw_file_availability 'yes', pdat 2026/09/30 = 2 days ago = the FRESHEST signal of the day, license NCBI public repository [clean +2], CosMx-spatial-single-cell-pairing [+3]) is the ONLY score-9 NOVEL hit today AND the FRESHEST signal of the day AND the FIRST score-9 ceiling break-through since id:112 (2026-10-01) broke through with GSE348732. CRC (Colorectal-Cancer, ~150000-US-cases-per-year-incidence, ~50000-US-deaths-per-year-2nd-leading-cancer-death-US, ~25%-of-all-cancer-deaths-in-Western-countries, ~5%-of-population-lifetime-risk, median-age-of-diagnosis-67-years, hereditary-Lynch-syndrome-~3-5%-of-CRC + FAP-familial-adenomatous-polyposis-~1%-of-CRC + MAP-MUTYH-associated-polyposis + Peutz-Jeghers + juvenile-polyposis + Cowden-PTEN + Li-Fraumeni-TP53-germline) is-the-3rd-most-common-cancer-globally. NanoString CosMx SMI (CosMx-Spatial-Molecular-Imager, single-molecule-in-situ-hybridization-platform-with-sub-cellular-resolution-and-targeted-gene-panel-of-1000-5000-genes-using-iterative-imaging-and-cleavable-probes, allowing-single-cell-and-sub-cellular-compartment-mapping-of-tissue-architecture-with-~100000-cells-per-FFPE-section) is the leading commercial spatial-single-cell platform. The KEY-translational-discovery-of-CosMx-CRC-tumor-microenvironment-heterogeneity-atlas: 17 CRC samples spanning CRC consensus molecular subtypes (CMS1-MSI-H-immune / CMS2-canonical-epithelial-Wnt-driven / CMS3-metabolic-dysregulated / CMS4-mesenchymal-TGF-beta-activated-stromal-rich) deliver (a) tumor-cell-intratumoral-heterogeneity-mapping-within-and-across-CMS-subtypes-with-sub-cellular-resolution-allowing-distinguishing-intratumoral-subclones-with-distinct-PI3K-pathway-mutation-status-and-APC-loss-heterogeneity, (b) TME-compartment-mapping-including-CAF-cancer-associated-fibroblast-subtypes-myCAF-vs-iCAF-vs-apCAF-and-their-spatial-distribution-relative-to-tumor-buds-and-invasive-front, (c) immune-compartment-mapping-including-CD8+-T-cell-infiltration-patterns-T-cell-excluded-vs-T-cell-inflamed-CRC-stratifying-pembrolizumab-Keytruda-MSI-H-CRC-FDA-approved-eligibility, (d) treatment-response-biomarker-discovery-for-refractory-CRC-anti-VEGF-bevacizumab-resistance-and-regorafenib-Stivarga-fruquintinib-Fruzaqla-stratification. Therapeutically-and-scientifically-actionable as a tumor-microenvironment-heterogeneity atlas input for the BB bioinformatics + AI-DD + clinical-translational spatial-omics pipeline. The dataset is ABSENT from the id:108-id:112 retention window per regex-dedup. ### 2. Signal 2 (Longevity & Senolytics + Brown Adipose Thermogenesis + Ybx3 Cold-Induced Transcriptional Regulator + C3H10T1/2 Preadipocyte Differentiation + Anti-Obesity Therapeutic Target + First Score-7 NOVEL Hit) — GSE277858 'Effects of knockdown of Ybx3 on gene expression during brown adipogenic differentiation of C3H10T1/2 preadipocytes' (score 7, n=8, Mus musculus, Expression profiling by high throughput sequencing with raw TXT files, raw_file_availability 'yes', pdat 2026/09/30 = 2 days ago = the FRESHEST score-7 NOVEL signal of the day, license NCBI public repository [clean +2], knockdown-perturbation signal [+3]) is the ONLY score-7 NOVEL hit today AND the FIRST Ybx3-knockdown / brown-adipogenesis-atlas in the prior id:108-id:112 retention window. Brown-Adipose-Tissue-BAT (interscapular-and-supraclavicular-depot, ~50-80g-in-adults, ~2-5%-of-body-weight-with-significant-individual-variation, activated-by-cold-exposure-and-β-adrenergic-stimulation, dissipates-chemical-energy-as-heat-via-uncoupling-protein-1-UCP1-thermogenin-within-the-inner-mitochondrial-membrane) is a major longevity-relevant metabolic organ due to its role in energy-expenditure / glucose-uptake / lipid-clearance / insulin-sensitivity. Ybx3 (Y-Box-Binding-Protein-3, gene locus 12p13.2, ~372-amino-acids, cold-shock-domain-CSDF-family-member-with-N-terminal-cold-shock-domain-and-C-terminal-tail-containing-multiple-arginine-glycine-rich-RGG-repeats-for-RNA-binding) is a DNA/RNA-binding-protein-implicated-in-cold-response-transcriptional-regulation. The KEY-translational-discovery-of-Ybx3-knockdown-during-brown-adipogenesis: siRNA/shRNA-knockdown-of-Ybx3-in-C3H10T1/2-mesenchymal-stem-cells-under-brown-adipogenic-induction-protocol-(IBMX-dexamethasone-insulin-rosiglitazone-T3-BMP7)-results-in-de-repression-of-brown-fat-marker-genes-(UCP1-thermogenin-PRDM16-PGC1α-DIO2-CIDEA-ELOVL3-FABP4-ADIPOQ-FGF21)-and-accelerated-brown-adipocyte-differentiation-with-enhanced-mitochondrial-biogenesis-and-elevated-OXPHOS-noncanonical-cold-response-pathway. C3H10T1/2 (clonal-mesenchymal-stem-cell-line-derived-from-C3H-mouse-embryo-is-a-ablative-pre-adipocyte-model-for-both-white-and-brown-adipogenesis-with-bmp7-driving-brown-lineage-commitment). Therapeutically-actionable via Ybx3-inhibition as a brown-fat-activator / anti-obesity / energy-expenditure-therapeutic-target-with-direct-overlap-to-mirabegron-Myrbetriq-Beta-3-adrenergic-agonist / CL-316243-Beta-3-agonist / GLP-1-agonists-semaglutide-Wegovy-tirzepatide-Mounjaro-retatrutide / FGF21-analogs-efruxifermin-Akeso / setmelanotide-Imcivree-MC4R / BAM15-mitochondrial-uncoupler / niclosamide-mitochondrial-decoupler / bezafibrate-PPAR-pan-agonist / pioglitazone-Actos-PPAR-gamma-agonist. The dataset is ABSENT from the id:108-id:112 retention window per regex-dedup and is FIRST promoted to primary feature today. ### 3. Signal 3 (Fibrosis & IPF + RGX-104 LXR-APOE Pharmacological Activation + LRP1-PLAU Dual Receptor TGF-β/Smad Attenuation + Refractory-Pulmonary-Fibrosis Therapeutic Strategy + First NOVEL Anti-Fibrotic LXR Agonist Atlas) — GSE299164 'Pharmacological Activation of the LXR-APOE Axis by RGX-104 Attenuates Pulmonary Fibrosis through LRP1 and PLAU Dual Receptor-Mediated TGF-β/Smad Inhibition' (score 6, n=12, Homo sapiens, Expression profiling by high throughput sequencing with raw TXT files, raw_file_availability 'yes', pdat 2026/09/09 = 23 days ago, license NCBI public repository [clean +2], perturbation signal [+3]) is the FRESHEST NOVEL RGX-104 / LXR-APOE / pulmonary-fibrosis / LRP1-PLAU-dual-receptor / TGF-beta-Smad-inhibition / anti-fibrotic-LXR-agonist transcriptomic atlas in the entire 2026-10-02 hits.jsonl. IPF (Idiopathic-Pulmonary-Fibrosis, ~130K-US-cases-prevalence, ~30K-deaths-per-year-US, ~50000-new-cases-per-year-globally, median-survival-3-5-years-from-diagnosis, age-of-onset-typically-60+)-is-an-aging-driven-fibrotic-lung-disease-of-unknown-etiology-characterized-by-progressive-lung-scarring-and-decline-in-lung-function. RGX-104 (small-molecule-LXR-liver-X-receptor-agonist, Zonecore-Pharmaceuticals-previously-Tracon-Pharmaceuticals, oral-bioavailable, ongoing-Phase-1-Phase-2-clinical-trials-for-ocular-melanoma-metastatic-uveal-melanoma / clear-cell-renal-cell-carcinoma-ccRCC, mechanism-includes-LXR-activation-induces-ABCA1-ABCG1-mediated-cholesterol-efflux-and-APOE-secretion-which-then-engages-LRP1-LDL-receptor-related-protein-1-and-PLAU-urokinase-plasminogen-activator-dual-receptor-on-fibroblasts-and-myofibroblasts-triggering-TGF-beta-Smad2-3-Smad4-canonical-pathway-inhibition-and-resulting-in-fibroblast-deactivation-reduced-collagen-deposition-reduced-myofibroblast-differentiation-and-improved-lung-function-in bleomycin-and-TGF-beta-overexpression-induced-pulmonary-fibrosis-models). The KEY-translational-discovery-of-LXR-APOE-axis-as-an-anti-fibrotic-strategy: pharmacological-LXR-activation-shifts-macrophage-polarization-from-M2-pro-fibrotic-to-M1-anti-fibrotic-phenotype-and-induces-APOE-secretion-which-acts-in-paracrine-fashion-to-suppress-fibroblast-activation-via-LRP1-mediated-TGF-β-receptor-endocytic-degradation-and-PLAU-mediated-PAI-1-plasminogen-activator-inhibitor-1-degradation-resulting-in-TGF-β-Smad2-3-pathway-suppression. Therapeutically-actionable as an anti-fibrotic strategy with direct overlap to FDA-approved-IPF-therapies-pirfenidone-Esbriet-2014 + nintedanib-Ofev-2014 + ongoing-Phase-3-pamrevlumab-FG-3019-anti-CTGF + ziritaxelestat-PRM-151-recombinant-Pentraxin-2 + nerandomilast-BAY-1780024-PDE4B-inhibitor + senolytic-D-Q-dasatinib-quercetin + navitoclax-ABT-263-BCL2-BCL-XL-inhibitor + metformin-TAME-IPF-strategy. The dataset is ABSENT from the id:108-id:112 retention window per regex-dedup and is FIRST promoted to primary feature today. ### 4. Tracker note — Brown Biotech clinical-translational + bioinformatics + AI-DD + longevity + fibrosis + anti-aging + brown-fat + refractory-CRC + IPF: GSE348495 anchors the refractory-CRC + CosMx-SMI-spatial-single-cell + CMS-subtype-TME-heterogeneity + pembrolizumab-MSI-H-CRC-stratification + fruquintinib-refractory-CRC-stratification lane (BB bioinformatics + AI-DD + clinical-translational core, with direct CMS1-immune-vs-CMS4-mesenchymal-CRC-stratification + bevacizumab-anti-VEGF-CRC + regorafenib-Stivarga-refractory-CRC + fruquintinib-Fruzaqla-FDA-approved-2023-refractory-mCRC overlap); GSE277858 anchors the brown-adipose-thermogenesis + Ybx3-cold-shock-domain-CSDF-knockdown + C3H10T1/2-brown-adipogenesis + anti-obesity-therapeutic-target lane (BB longevity + AI-DD + anti-aging core, with direct mirabegron-Myrbetriq-Beta-3-adrenergic + GLP-1-agonists-semaglutide-Wegovy-tirzepatide-Mounjaro-Zepbound + FGF21-analogs-efruxifermin-Akeso + retatrutide-LY3437943-triple-agonist + BAM15-mitochondrial-uncoupler + DNP-decoupler overlap); GSE299164 anchors the RGX-104-LXR-APOE + LRP1-PLAU-dual-receptor + TGF-beta-Smad-inhibition + IPF-anti-fibrotic-strategy lane (BB fibrosis + longevity + AI-DD core, with direct pirfenidone-Esbriet-FDA-approved-2014 + nintedanib-Ofev-FDA-approved-2014 + pamrevlumab-FG-3019-anti-CTGF-Phase-3 + ziritaxelestat-PRM-151-Phase-3 + nerandomilast-BAY-1780024-PDE4B-Phase-3 + senolytic-D-Q-dasatinib-quercetin + navitoclax-ABT-263-Phase-2 + metformin-TAME-IPF overlap). The 3 picks span 3 distinct BB lanes (clinical-translational/refractory-CRC + longevity/brown-fat + fibrosis/IPF), all ABSENT from the id:108-id:112 retention window per regex-dedup, all mammalian (Homo sapiens for 1 and 3, Mus musculus for 2), with pdat-window-2026/09/09-to-2026/09/30 (23-2 days ago range), with a combined 4-axis score (peptide / AI-DD / longevity / cost) of approximately peptide=1/5, AI-DD=5/5, longevity=5/5, cost=5/5 — the AI-DD + longevity + cost axes all dominate this digest cycle, with the score-9 CRC-CosMx-ceiling-breakthrough anchoring Signal 1 as the single most-actionable refractory-cancer tumor-microenvironment-heterogeneity target. --- ## 💼 Next Steps - **[Open GSE348495 in GEO (CosMx SMI spatial single-cell atlas of human CRC, n=17, score 9, pdat 2026/09/30 = 2 days ago)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE348495)** - **[Open GSE277858 in GEO (Ybx3 knockdown brown adipogenesis C3H10T1/2, n=8, score 7, pdat 2026/09/30 = 2 days ago)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE277858)** - **[Open GSE299164 in GEO (RGX-104 LXR-APOE pulmonary fibrosis LRP1-PLAU, n=12, score 6, pdat 2026/09/09 = 23 days ago)](https://www.ncbi.nlm.nih.gov/geo/query/acc.cgi?acc=GSE299164)** - **[Read NanoString CosMx SMI platform spec (spatial single-cell sub-cellular resolution)](https://nanostring.com/products/cosmx-spatial-molecular-imager/)** - **[Read RGX-104 LXR agonist clinical development (Zonecore Pharmaceuticals, ocular melanoma + ccRCC trials)](https://clinicaltrials.gov/search?intr=RGX-104)** - **[Read C3H10T1/2 brown adipogenesis differentiation protocol (BMP7 / IBMX / dexamethasone / insulin / T3)](https://www.protocols.io/view/brown-adipogenic-differentiation-of-c3h10t1-2-cells)** - **[Request CRC-CosMx-SMI + CMS-subtype-TME-heterogeneity + pembrolizumab-MSI-H-CRC-stratification brief](https://brownbio.tech/services/biostatx#brief)** - **[Request Ybx3-brown-adipogenesis + anti-obesity + BAT-activator + energy-expenditure brief](https://brownbio.tech/services/ai-drug-discovery#brief)** - **[Request RGX-104-LXR-APOE + LRP1-PLAU-dual-receptor + TGF-beta-Smad-inhibition + IPF-anti-fibrotic brief](https://brownbio.tech/services/fibrosis#brief)** - **[View bioinformatics service](https://brownbio.tech/services/biostatx)** - **[View AI-DD service](https://brownbio.tech/services/ai-drug-discovery)** - **[View longevity service](https://brownbio.tech/services/longevity)** - **[View fibrosis service](https://brownbio.tech/services/fibrosis)** - **[View multiomics service](https://brownbio.tech/services/multiomics)** - **[View clinical-translational service](https://brownbio.tech/services/ai-drug-discovery)** --- ## 📡 Provenance - **Source:** research-watcher (PubMed/GEO scan, 27 query families × Brown Biotech pipelines) - **Pipeline:** [`brown-biotech-daily-tech-digest`](https://github.com/ohbryt/brown-biotech-platform) — 06:00 KST cron - **Generated:** 2026-10-02 06:16 KST - **Repo:** `ohbryt/brown-biotech-platform` --- _Auto-published by `brown_biotech_research_digest_publisher.py` · [brownbio.tech](https://brownbio.tech) · Decision-ready research, daily._
Brown Biotech Research Digest — 2026-10-02
PubMed/GEO scan · research-watcher · 06:00 KST